INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that Alabama Fertility, a leading reproductive medicine practice in Birmingham, Alabama, has expanded its scope of reproductive treatments with the addition of INVOcell.
INVOcell has the ability to significantly transform the way in which doctors assist infertility patients to become pregnant in a simpler, more natural and cost-effective manner. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The simplistic INVO can be easily performed in an appropriately trained physician’s office without the need for expensive overhead.
Beth A. Malizia, MD, a specialist in infertility and reproductive surgery at Alabama Fertility, said, “We are pleased to add INVOcell to our list of advanced fertility services. Infertility is a highly frustrating condition that afflicts many couples and individuals in Alabama and the greater southeastern U.S. We are dedicated to providing a broad scope of diagnosis and treatment options. INVOcell is a unique, cost effective, alternative that may result in pregnancy when other treatment options have failed. We believe that INVOcell is a fantastic addition to our scope of services.”
About Alabama Fertility
At Alabama Fertility we are dedicated to helping patients and couples cope with the often complex problems that can affect reproduction. We assist patients with infertility, repeated miscarriages, reproductive counseling and surgery. Alabama Fertility is an international referral center for complex reproductive problems including endometriosis, uterine fibroids, congenital abnormalities of the reproductive system and infertility. We offer the most advanced methods of diagnosis and treatment including assisted reproductive techniques and advanced endoscopic surgery. At Alabama Fertility each patient is treated with the understanding and compassion that these complex reproductive problems require. Our specialty trained, highly experienced physicians will provide you with guidance and support in a reassuring and private setting.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
